Catharanthalog
| Clinical data | |
|---|---|
| Other names | CAG |
| Drug class | Non-hallucinogenic serotonin 5-HT2A receptor partial agonist |
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H18N2O2 |
| Molar mass | 258.321 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure.[1][2] It is known to act as a serotonin 5-HT2A receptor partial agonist.[2] The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT2A receptor antagonist ketanserin.[2] Catharanthalog is said to have relatively low blood–brain barrier permeability owing to relatively low lipophilicity.[2] It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2] The drug was first described in the scientific literature by 2025.[1][2]
- ^ a b Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A (June 2025). "Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives". ACS Chemical Neuroscience. 16 (12): 2163–2177. doi:10.1021/acschemneuro.5c00152. PMC 12183689. PMID 40474592.
In an oxaliplatin-induced neuropathic pain model, catharanthalog (CAG), noribogainalog (nor-IBG), and another ibogalog derivative, PNU-22394 also demonstrated consistent analgesic ecacy without observable toxicity.92
- ^ a b c d e f Arias HR, Micheli L, Jensen AA, Galant S, Vandermoere F, Venturi D, et al. (March 2025). "Ibogalogs decrease neuropathic pain in mice through a mechanism involving crosstalk between 5-HT2A and mGlu2 receptors" (PDF). Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 184 117887. doi:10.1016/j.biopha.2025.117887. PMID 39938347.